Confirmed by the executive committee, the additional capital will fuel the expansion and investment capacity of the Sanofi Ventures investment team on a global scale. The team partners across all stages of the private company lifecycle, from Seed to Series B and beyond.
Sanofi Ventures invests in innovators working in areas including immunology and inflammation, rare diseases, oncology, cell and gene therapy, vaccines, and digital health and data science. Serving as a financial partner to top-tier, early-to-mid stage portfolio companies, the fund also supports future efforts for business development and M&A opportunities within Sanofi.
